Lung cancer PDX

Patient Derived Xenograft (PDX) Mouse Models and Efficacy Services
Leukemias PDXStomach Cancer PDXPancreatic Cancer PDXOvarian Cancer PDXLung cancer PDXColorectal Cancer PDXBreast Cancer PDXBladder Cancer PDX
Humanized Immune Checkpoint Mouse Models and Efficacy Services
Anti-PD1 Drug-resistant Tumor ModelsIn Vivo Efficacy Studies Using TIGIT Humanized ModelsPDL1 Humanized Mouse ModelPD1 Humanized Mouse ModelsOX40 Humanized Mouse ModelsIn vivo Efficacy Test in LAG3 Humanized Mouse ModelsIn vivo Efficacy Test in GITR Humanized Mouse ModelCTLA4 Humanized Mouse ModelsIn vivo Efficacy Test in CD137 Humanized Models

Angiogenesis is closely associated with tumorigenesis, progression, metastasis, and prognosis of lung cancer. This also include neovascularization with unrestricted proliferation of tumor cells. In addition, anti-angiogenic monotherapy has limited clinical efficacy, and drug resistance is evident. As a result, the "A+A" strategy (the combination of two or more anti-angiogenic medications targeting various angiogenic signaling pathways) is thought to achieve more potent anti-tumor effects. Avastin and Erlotinib, for example, were recently approved for the treatment of NSCLC with EGFR-activating mutations, and the results were verified by a phase III clinical trial (NEJ026).

At present, GemPharmatech' extensive collection possesses 6 cases of PDX tumor samples of Lung Cancer.


PDX ID 

Histological type  

 Grade 

  Stage  

WES 

RNA-seq

LC00136

Lung Squamous Cell Carcinoma

Low to medium differentiation

N/A

Y

Y

LC00140

Lung Squamous Cell Carcinoma

Moderate-severe differentiation

N/A

Y

Y

LC00143

Lung Adenocarcinoma

N/A

ⅡA (T2b N0 cM0)

Y

Y

LC00167

Lung Squamous Cell Carcinoma

N/A

N/A

N/A

Y

LC00202

Small Cell Lung Cancer

Poorly differentiated

N/A

YY

LC00256

Lung Squamous Cell Carcinoma

Moderately differentiated

ⅠA3(pT1cN0cM0)

YY


TALK WITH OUR EXPERTS

GemPharmatech is committed to protecting and respecting your privacy, and we'll only use your personal information to administer your account and to provide the products and services you requested from us. From time to time, we would like to contact you about our products and services, as well as other content that may be of interest to you. If you consent to us contacting you for this purpose, please click below to say how you would like us to contact you:

In order to provide you with the content requested, we need to store and process your personal data. If you consent to us storing your personal data for this purpose, please click the checkbox below.

You can unsubscribe from these communications at any time. For more information on how to unsubscribe, our privacy practices, and how we are committed to protecting and respecting your privacy, please review our Privacy Policy.